AR and Familial prostate cancer: To further investigate the biological pressures for the selection of these two AR mutations, we used a reporter luciferase construct in prostate cancer cells transfected with AR wild-type or a combination of the detected mutations and treated with a range of ligands, including progesterone and prednisone previously suggested as contributing to resistance against abiraterone17–19 (Fig. 3f).